Eczema (Atopic Dermatitis) Clinical Trials in San Antonio

View 44 new treatments for Eczema (Atopic Dermatitis) in San Antonio, TX. Every day, Power helps hundreds of Eczema (Atopic Dermatitis) patients connect with leading medical research.
View 32 trials in San Antonio
Filter (32)

Dupilumab for Eczema

Regeneron Clinic, San Antonio + 2 more

This trial is testing a medication for treating eczema in people with skin of color. Eczema causes itchy, dry, and cracked skin. The medication aims to reduce these symptoms by calming the immune system. The study will also look at side effects, how much of the drug is in the blood at different times, and improvements in quality of life and mental health.Show More
Waitlist

No Placebo Trial

Phase 4
Est. 3 - 6 Weeks
Clinical Trial Management
Study Director

Nemolizumab for Eczema

Galderma Clinic, San Antonio + 1 more

Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description
Waitlist

No Placebo Trial

Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team

Upadacitinib + Topical Corticosteroids for Eczema

AbbVie Clinic, San Antonio + 1 more

The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.Show More
Waitlist
Phase 3
Est. 3 - 12 Weeks
ABBVIE INC.
Study Director

Tralokinumab for Atopic Hand Eczema

LEO Clinic, San Antonio + 1 more

The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. This will be judged by a range of assessments that rate the severity and extent of atopic hand eczema and its symptoms, as well as general health status and quality of life. The trial will last for up to 40 weeks. There will be up to 15 visits, 3 of which will be conducted by phone. The first part of the trial is called a screening period and will last up to 4 weeks. For the first 16 weeks after screening, trial participants will receive either tralokinumab or dummy injections every two weeks. After the first 16 weeks, all trial participants will receive tralokinumab injections every two weeks for 16 weeks. The last part of the trial is a period of 4 weeks after the end of treatment period, where trial participants are off the drug for safety follow-up.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
Medical Expert
Study Director

Amlitelimab for Atopic Dermatitis (COAST 2)

Sanofi Clinic, San Antonio + 1 more

This trial tests amlitelimab injections for patients aged 12 and older with moderate to severe atopic dermatitis that isn't controlled by topical treatments. The injections aim to reduce inflammation and symptoms by targeting specific immune pathways.Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
Unregistered Study Lead
Research Team

Abrocitinib for Atopic Dermatitis/Eczema

Pfizer Clinic, San Antonio + 2 more

This trial is testing a pill called Abrocitinib to help people aged 12 and older with severe eczema. It aims to see if the pill can reduce inflammation and itching by blocking certain body chemicals. The study includes patients who have already participated in a related study.Show More
Waitlist
Phase 3
Est. 5 - 8 Weeks
Pfizer CT.gov Call Center
Study Director

Lebrikizumab for Eczema

Eli Lilly Clinic, San Antonio + 2 more

This trial is testing the safety and effectiveness of lebrikizumab, a medication for eczema. It targets people with moderate-to-severe atopic dermatitis, including those from previous studies and new participants. Lebrikizumab works by blocking a protein that causes inflammation and itching.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 3 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

Rocatinlimab for Atopic Dermatitis

Amgen Clinic, San Antonio + 1 more

This trial is testing a medication called rocatinlimab to see if it works and is safe for teenagers. The medication can be used by itself or with other treatments. It aims to help by interacting with the immune system.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
MD
Study Director

Amlitelimab for Atopic Dermatitis (SHORE)

Sanofi Clinic, San Antonio + 2 more

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe atopic dermatitis (AD) with a history of inadequate response of topical treatment, on background topical corticosteroid (TCS) and/or topical calcineurin inhibitor (TCI). The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared with placebo in participants with moderate to severe AD aged 12 years and older on background TCS and/or TCI. Study details include: At the end of the treatment period, participants will have an option to enter a separate study: the blinded extension study EFC17600 (ESTUARY). For participants not entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 44 weeks including a 2 to 4-week screening, a 24-week randomized double-blind period, and a 16-week safety follow-up. For participants entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 28 weeks including a 2 to 4-week screening and a 24-week randomized double-blind period. The total treatment duration will be up to 24 weeks. The total number of visits will be up to 10 visits (or 9 visits for those entering the blinded extension study EFC17600 (ESTUARY).Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team

Amlitelimab for Atopic Dermatitis (COAST 1)

Sanofi Clinic, San Antonio + 1 more

This trial tests an injectable treatment called amlitelimab for people aged 12 and older with moderate to severe eczema that doesn't respond well to creams or ointments. The treatment aims to reduce skin inflammation and itching by blocking specific proteins in the immune system. The study will evaluate how effective and safe amlitelimab is.Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
Clinical Sciences & Operations
Study Director
Page 1 of 4

Frequently Asked Questions

How much do eczema clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do eczema clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across eczema trials in San Antonio, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for eczema patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

Where in San Antonio is research being conducted for eczema?

In San Antonio, Texas Dermatology and Laser Specialists is conducting eczema clinical trials. Additionally, Progressive Clinical Research is also involved in these trials, with approximately 28 trials ongoing as of 2024.

What promising new drugs are being tested?

In San Antonio, eczema research is focusing on treatments like Monoclonal Antibodies and Janus Kinase (JAK) Inhibitors. Notable drugs being studied include Dupilumab, Tralokinumab, and Upadacitinib.